Cantor Fitzgerald initiated coverage on shares of Equillium (NASDAQ:EQ) in a report released on Wednesday morning, Price Targets.com reports. The firm issued an overweight rating and a $14.00 price objective on the stock. Cantor Fitzgerald also issued estimates for Equillium’s FY2021 earnings at ($1.22) EPS and FY2022 earnings at ($1.50) EPS.
Several other equities research analysts have also commented on EQ. HC Wainwright reiterated a buy rating and issued a $12.00 price objective on shares of Equillium in a research report on Wednesday, July 14th. SVB Leerink reissued a buy rating on shares of Equillium in a research note on Tuesday, June 15th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of Buy and a consensus target price of $12.75.
Equillium stock opened at $6.38 on Wednesday. Equillium has a 52 week low of $3.47 and a 52 week high of $11.33. The company has a quick ratio of 19.99, a current ratio of 19.99 and a debt-to-equity ratio of 0.12. The firm’s 50-day simple moving average is $5.81 and its 200 day simple moving average is $6.27. The firm has a market capitalization of $187.46 million, a PE ratio of -4.87 and a beta of 1.61.
In other news, CFO Jason A. Keyes sold 5,000 shares of the company’s stock in a transaction dated Tuesday, July 27th. The shares were sold at an average price of $5.72, for a total transaction of $28,600.00. Following the completion of the transaction, the chief financial officer now owns 17,711 shares of the company’s stock, valued at approximately $101,306.92. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Corporate insiders own 32.70% of the company’s stock.
Several large investors have recently modified their holdings of the company. Deutsche Bank AG grew its holdings in shares of Equillium by 1.8% during the 2nd quarter. Deutsche Bank AG now owns 356,461 shares of the company’s stock worth $2,100,000 after purchasing an additional 6,461 shares during the period. Northern Trust Corp boosted its stake in shares of Equillium by 42.9% during the 1st quarter. Northern Trust Corp now owns 34,055 shares of the company’s stock valued at $243,000 after buying an additional 10,228 shares during the last quarter. Citadel Advisors LLC purchased a new position in shares of Equillium during the 1st quarter valued at approximately $153,000. Geode Capital Management LLC boosted its stake in shares of Equillium by 16.7% during the 2nd quarter. Geode Capital Management LLC now owns 150,582 shares of the company’s stock valued at $886,000 after buying an additional 21,510 shares during the last quarter. Finally, Victory Capital Management Inc. boosted its stake in shares of Equillium by 1.0% during the 2nd quarter. Victory Capital Management Inc. now owns 2,896,875 shares of the company’s stock valued at $17,063,000 after buying an additional 28,017 shares during the last quarter. Institutional investors and hedge funds own 24.20% of the company’s stock.
Equillium, Inc engages in the development of products for severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. Its product pipeline includes EQ001, which is a monoclonal antibody that selectively targets the novel immune checkpoint receptor CD6. The company was founded by Daniel Mark Bradbury, Bruce D.
Featured Article: What is an Initial Coin Offering (ICO)?
Receive News & Ratings for Equillium Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Equillium and related companies with MarketBeat.com's FREE daily email newsletter.